Somatropin-Related Study "Ngenla" Trial Status Updated Oct 7, 2026

On October 7, 2026, a trial record update was logged for the study titled "Ngenla Subcutaneous Injection Special Investigation," registered as NCT05602766. The trial status is listed as active, not recruiting, as of this date. No phase information was provided in the record. This entry relates to somatropin recombinant, a compound currently classified under unapproved research status. No results have been posted for this trial according to the available data. No efficacy or safety outcomes can be inferred from this status update alone. The update reflects only the trial's current recruitment and activity status, not any findings or conclusions. Readers should note that an active, not recruiting status typically means the study is ongoing but not currently enrolling new participants, though no further detail was given. No additional information regarding study design, objectives, or endpoints was included in this event record. For more background on somatropin recombinant, readers can consult the compound overview for further context.